articleJournal of Thrombosis and HaemostasisOct 20, 2019Closed access

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

RDRobert D. McBaneWEWaldemar E. WysokińskiJLJennifer Le‐RademacherTZTyler ZemlaAAAneel A. Ashrani

Mayo Clinic · Mayo Clinic in Florida · +8 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

576
total citations
FWCI
62.29
Percentile
100%
References
34
Citations per year

Authors

17

Topics & keywords

Topics
Keywords
  • Apixaban
  • Medicine
  • Hazard ratio
  • Internal medicine
  • Venous thromboembolism
  • Randomized controlled trial
  • Low molecular weight heparin
  • Confidence interval
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding